BEAM Live signals | Maximize Profits with Getagraph.com

BUY 51776 min ago

@ $35.38

Issued: 21 Mar 2024 @ 14:07

Return: -38.38%

Previous signal: Mar 20 - 11:15

Previous signal: Sell

Return: 1.94 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 13:02):

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States...

Stats
Today's Volume	368 495
Average Volume	1.54M
Market Cap	1.78B
EPS	$0 ( 2024-02-27 )
Next earnings date	( $-1.450 ) 2024-05-08
Last Dividend	$0.225 ( 2014-02-04 )
Next Dividend	$0 ( N/A )
P/E	-13.37
ATR14	$0.0270 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Simon Amy	Sell	7 157	Common Stock
2024-04-02	Simon Amy	Sell	16 530	Common Stock
2024-04-01	Bellon Christine	Sell	3 401	Common Stock
2024-04-01	Burrell Terry-ann	Sell	5 446	Common Stock
2024-04-01	Evans John M.	Sell	18 102	Common Stock

INSIDER POWER
-13.27
Last 98 transactions
Buy: 1 500 214 \| Sell: 1 914 982

Volume Correlation

Long: -0.09 (neutral)

Short: -0.77 (moderate negative)

Signal:(58.118) Neutral

Beam Therapeutics Inc Correlation

10 Most Positive Correlations
TUEM	0.951
TWST	0.942
SGMO	0.93
CSSE	0.929
ROST	0.927
MDRX	0.926
GRPN	0.924
RKDA	0.924
HMST	0.923
AFIB	0.923

10 Most Negative Correlations
WIRE	-0.933
CPTA	-0.928
TYHT	-0.928
ZGNX	-0.926
HTBI	-0.92
VC	-0.92
PAE	-0.919
SGEN	-0.919
RAM	-0.916
EBSB	-0.91

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Beam Therapeutics Inc Correlation - Currency/Commodity

0.67
( moderate )

0.76
( moderate )

0.00
( neutral )

0.60
( weak )

-0.35
( neutral )

-0.42
( neutral )

Beam Therapeutics Inc Financials

Annual	2023
Revenue:	$377.71M
Gross Profit:	$357.70M (94.70 %)
EPS:	$-1.720

FY	2023
Revenue:	$377.71M
Gross Profit:	$357.70M (94.70 %)
EPS:	$-1.720

FY	2022
Revenue:	$60.92M
Gross Profit:	$38.34M (62.94 %)
EPS:	$-3.76

FY	2021
Revenue:	$51.84M
Gross Profit:	$51.84M (100.00 %)
EPS:	$-5.77

Financial Reports:

No articles found.

Beam Therapeutics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Beam Therapeutics Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.443 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.190	2011-11-07
Last Dividend	$0.225	2014-02-04
Next Dividend	$0	N/A
Payout Date	2014-03-03
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	$2.16	--
Avg. Dividend % Per Year	0.00%	--
Score	1.6	--
Div. Sustainability Score	1.443
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-19)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.60

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.318	1.500	-6.36	-9.54	[0 - 0.5]
returnOnAssetsTTM	-0.0823	1.200	-2.74	-3.29	[0 - 0.3]
returnOnEquityTTM	-0.144	1.500	-2.71	-4.07	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	5.89	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.79	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.12	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.119	-1.500	8.02	-10.00	[0 - 0.6]
interestCoverageTTM	-5.10	1.000	-3.00	-3.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.845	2.00	-0.615	-1.230	[0 - 30]
freeCashFlowPerShareTTM	-2.26	2.00	-1.131	-2.26	[0 - 20]
debtEquityRatioTTM	0.176	-1.500	9.29	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.928	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.467	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.862	1.000	-5.90	-5.90	[0.2 - 2]
assetTurnoverTTM	0.259	0.800	-1.608	-1.287	[0.5 - 2]
Total Score				1.443

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-14.54	1.000	-1.570	0	[1 - 100]
returnOnEquityTTM	-0.144	2.50	-1.744	-4.07	[0.1 - 1.5]
freeCashFlowPerShareTTM	-2.26	2.00	-0.754	-2.26	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.845	2.00	-0.615	-1.230	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.273	1.500	-5.15	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.395	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.64

Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.